Graeme R Robb
Overview
Explore the profile of Graeme R Robb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark F, Robb G, Cole D, Michel J
J Chem Theory Comput
. 2024 Sep;
PMID: 39254715
Alchemical absolute binding free energy (ABFE) calculations have substantial potential in drug discovery, but are often prohibitively computationally expensive. To unlock their potential, efficient automated ABFE workflows are required to...
2.
Quinn T, Giblin K, Thomson C, Boerth J, Bommakanti G, Braybrooke E, et al.
J Med Chem
. 2024 Aug;
67(16):14210-14233.
PMID: 39132828
Casitas B-lymphoma proto-oncogene-b (Cbl-b) is a RING finger E3 ligase that has an important role in effector T cell function, acting as a negative regulator of T cell, natural killer...
3.
Smith J, Barlaam B, Beattie D, Bradshaw L, Chan H, Chiarparin E, et al.
J Med Chem
. 2024 Jul;
67(16):13604-13638.
PMID: 39080842
PRMT5, a type 2 arginine methyltransferase, has a critical role in regulating cell growth and survival in cancer. With the aim of developing MTA-cooperative PRMT5 inhibitors suitable for MTAP-deficient cancers,...
4.
Atkinson S, Bagal S, Argyrou A, Askin S, Cheung T, Chiarparin E, et al.
J Med Chem
. 2024 Mar;
67(6):4541-4559.
PMID: 38466661
The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free...
5.
Pike K, Hunt T, Barlaam B, Benstead D, Cadogan E, Chen K, et al.
J Med Chem
. 2024 Feb;
67(4):3090-3111.
PMID: 38306388
The inhibition of ataxia-telangiectasia mutated (ATM) has been shown to chemo- and radio-sensitize human glioma cells in vitro and therefore might provide an exciting new paradigm in the treatment of...
6.
Mfuh A, Boerth J, Bommakanti G, Chan C, Chinn A, Code E, et al.
J Med Chem
. 2024 Jan;
67(2):1500-1512.
PMID: 38227216
Casitas B-lymphoma proto-oncogene-b (Cbl-b), a member of the Cbl family of RING finger E3 ubiquitin ligases, has been demonstrated to play a central role in regulating effector T-cell function. Multiple...
7.
Kettle J, Bagal S, Barratt D, Bodnarchuk M, Boyd S, Braybrooke E, et al.
J Med Chem
. 2023 Jul;
66(13):9147-9160.
PMID: 37395055
The glycine to cysteine mutation at codon 12 of Kirsten rat sarcoma (KRAS) represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based...
8.
Cumming I, Degorce S, Aagaard A, Braybrooke E, Davies N, Diene C, et al.
Bioorg Med Chem
. 2022 Apr;
63:116729.
PMID: 35439688
In this article, we report the discovery of a series of pyrimidopyridones as inhibitors of IRAK4 kinase. From a previously disclosed 5-azaquinazoline series, we found that switching the pyridine ring...
9.
Balazs A, Carbajo R, Davies N, Dong Y, Hird A, Johannes J, et al.
J Med Chem
. 2021 Mar;
64(5):2849.
PMID: 33646774
No abstract available.
10.
Degorce S, Aagaard A, Anjum R, Cumming I, Diene C, Fallan C, et al.
Bioorg Med Chem
. 2020 Oct;
28(23):115815.
PMID: 33091850
In this article, we report our efforts towards improving in vitro human clearance in a series of 5-azaquinazolines through a series of C4 truncations and C2 expansions. Extensive DMPK studies...